DYN logo

Dyne Therapeutics (DYN) Cash and cash equivalents

annual cash & cash equivalents:

$435.45M+$313.82M(+258.02%)
December 31, 2024

Summary

  • As of today (May 29, 2025), DYN annual cash & cash equivalents is $435.45 million, with the most recent change of +$313.82 million (+258.02%) on December 31, 2024.
  • During the last 3 years, DYN annual cash & cash equivalents has risen by +$234.62 million (+116.83%).
  • DYN annual cash & cash equivalents is now at all-time high.

Performance

DYN Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherDYNbalance sheet metrics

quarterly cash & cash equivalents:

$472.25M+$36.81M(+8.45%)
March 31, 2025

Summary

  • As of today (May 29, 2025), DYN quarterly cash & cash equivalents is $472.25 million, with the most recent change of +$36.81 million (+8.45%) on March 31, 2025.
  • Over the past year, DYN quarterly cash & cash equivalents has increased by +$200.22 million (+73.60%).
  • DYN quarterly cash & cash equivalents is now -22.35% below its all-time high of $608.20 million, reached on June 30, 2024.

Performance

DYN quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherDYNbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

DYN Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+258.0%+73.6%
3 y3 years+116.8%+219.2%
5 y5 years+2876.0%-

DYN Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+258.0%-22.4%+288.3%
5 y5-yearat high+2876.0%-22.4%+288.3%
alltimeall timeat high+5260.0%-22.4%+3127.6%

DYN Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$472.25M(+8.5%)
Dec 2024
$435.45M(+258.0%)
$435.45M(-18.2%)
Sep 2024
-
$532.16M(-12.5%)
Jun 2024
-
$608.20M(+123.6%)
Mar 2024
-
$272.04M(+123.7%)
Dec 2023
$121.63M(-29.3%)
$121.63M(-6.6%)
Sep 2023
-
$130.28M(-22.3%)
Jun 2023
-
$167.61M(-7.5%)
Mar 2023
-
$181.11M(+5.2%)
Dec 2022
$172.15M
$172.15M(+18.8%)
Sep 2022
-
$144.90M(+6.6%)
DateAnnualQuarterly
Jun 2022
-
$135.98M(-8.1%)
Mar 2022
-
$147.97M(-26.3%)
Dec 2021
$200.82M(-33.2%)
$200.82M(-12.3%)
Sep 2021
-
$229.04M(-11.4%)
Jun 2021
-
$258.38M(-16.9%)
Mar 2021
-
$310.95M(+3.4%)
Dec 2020
$300.85M(+1956.1%)
$300.85M(-20.7%)
Sep 2020
-
$379.61M(+162.0%)
Jun 2020
-
$144.87M(+890.1%)
Dec 2019
$14.63M(+80.1%)
$14.63M
Dec 2018
$8.12M
-

FAQ

  • What is Dyne Therapeutics annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Dyne Therapeutics?
  • What is Dyne Therapeutics annual cash & cash equivalents year-on-year change?
  • What is Dyne Therapeutics quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Dyne Therapeutics?
  • What is Dyne Therapeutics quarterly cash & cash equivalents year-on-year change?

What is Dyne Therapeutics annual cash & cash equivalents?

The current annual cash & cash equivalents of DYN is $435.45M

What is the all time high annual cash & cash equivalents for Dyne Therapeutics?

Dyne Therapeutics all-time high annual cash & cash equivalents is $435.45M

What is Dyne Therapeutics annual cash & cash equivalents year-on-year change?

Over the past year, DYN annual cash & cash equivalents has changed by +$313.82M (+258.02%)

What is Dyne Therapeutics quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of DYN is $472.25M

What is the all time high quarterly cash & cash equivalents for Dyne Therapeutics?

Dyne Therapeutics all-time high quarterly cash & cash equivalents is $608.20M

What is Dyne Therapeutics quarterly cash & cash equivalents year-on-year change?

Over the past year, DYN quarterly cash & cash equivalents has changed by +$200.22M (+73.60%)
On this page